|
Chapter 1 Introduction: Biotechnology---An Ever Expanding Toolbox for Medicine |
|
|
1 | (26) |
|
|
|
|
|
1 | (1) |
|
1.2 Molecular Disease and DNA |
|
|
2 | (3) |
|
1.3 Genetic Engineering and Its Controversial Beginning |
|
|
5 | (3) |
|
1.4 Monoclonal Antibodies |
|
|
8 | (1) |
|
|
|
9 | (3) |
|
1.6 Whole Genome Sequencing---A Weapon Against Antimicrobial Resistance |
|
|
12 | (1) |
|
1.7 CRISPR: A New Gene Editing Tool and Controversy |
|
|
13 | (2) |
|
|
|
15 | (1) |
|
|
|
16 | (2) |
|
|
|
18 | (1) |
|
1.11 Impact in the Clinic---Eye Disease |
|
|
18 | (1) |
|
1.12 Cellular Therapy: A New Disruptive Technology |
|
|
19 | (1) |
|
|
|
20 | (1) |
|
|
|
21 | (1) |
|
|
|
22 | (5) |
|
|
|
23 | (4) |
|
Chapter 2 Biopharmaceutical Proteins: The Manufacturing Challenge |
|
|
27 | (27) |
|
|
|
|
|
|
|
27 | (1) |
|
2.2 The Emergence of a New Technology |
|
|
28 | (10) |
|
2.2.1 Other Host Organisms for Production |
|
|
32 | (1) |
|
2.2.2 Mammalian Cell Culture |
|
|
32 | (4) |
|
2.2.3 Alternative Production Systems |
|
|
36 | (1) |
|
2.2.4 Generating Cells for the Production Process |
|
|
37 | (1) |
|
2.3 Monoclonal Antibody Technology |
|
|
38 | (3) |
|
2.4 Manufacturing Challenges: Process Technology |
|
|
41 | (5) |
|
2.4.1 Growing Cells to Make Enough Product |
|
|
42 | (1) |
|
2.4.2 Making the Right Product |
|
|
43 | (1) |
|
2.4.3 Recovering the Product |
|
|
44 | (1) |
|
2.4.4 Product Purification |
|
|
44 | (1) |
|
2.4.5 Enhancing the Product's Medicinal Effect |
|
|
45 | (1) |
|
2.4.6 Preparing the Final Product |
|
|
46 | (1) |
|
|
|
46 | (5) |
|
2.5.1 Economic Factors---Cost of Goods |
|
|
47 | (1) |
|
2.5.2 Geographic Factors---A Global Industry |
|
|
47 | (1) |
|
2.5.3 Scientific Factors---New Products and Stratified Medicine |
|
|
47 | (1) |
|
2.5.4 Choice of Organisms for Future Production |
|
|
48 | (1) |
|
2.5.5 Future Manufacturing Plants |
|
|
49 | (1) |
|
2.5.6 Process Analytical and Control Technology |
|
|
50 | (1) |
|
|
|
51 | (3) |
|
|
|
51 | (3) |
|
Chapter 3 Vaccines: The Recombinant Revolution |
|
|
54 | (18) |
|
|
|
|
|
54 | (1) |
|
|
|
55 | (6) |
|
|
|
61 | (5) |
|
3.4 Influenza Vaccine (Flublok) |
|
|
66 | (2) |
|
|
|
68 | (4) |
|
|
|
69 | (3) |
|
Chapter 4 Monoclonal Antibodies: A Revolution in the Transformation of Healthcare |
|
|
72 | (25) |
|
|
|
|
|
72 | (1) |
|
4.2 What is a Monoclonal Antibody |
|
|
73 | (1) |
|
4.3 Understanding the Nature of Immunity |
|
|
73 | (2) |
|
4.4 Sourcing Antibodies---The Road to Monoclonal Antibodies |
|
|
75 | (1) |
|
4.5 A Revolutionary Tool for Medical Laboratory Research |
|
|
76 | (1) |
|
4.6 A New Tool for Diagnostics |
|
|
77 | (1) |
|
4.7 The Road to Therapeutics |
|
|
78 | (1) |
|
4.8 A Hesitant Start in Therapeutics |
|
|
79 | (1) |
|
4.9 Engineering Human Monoclonal Antibodies |
|
|
80 | (5) |
|
4.9.1 Humanising Murine Antibodies |
|
|
82 | (1) |
|
4.9.2 Fully Human Antibodies |
|
|
82 | (3) |
|
4.10 The Changing Composition of Mabs |
|
|
85 | (1) |
|
|
|
86 | (3) |
|
4.11.1 Auto-immune Disorders |
|
|
88 | (1) |
|
|
|
88 | (1) |
|
|
|
89 | (1) |
|
|
|
89 | (1) |
|
|
|
90 | (2) |
|
|
|
92 | (5) |
|
|
|
93 | (4) |
|
Chapter 5 The Changing Fortune of Cancer Immunotherapy |
|
|
97 | (29) |
|
|
|
|
|
97 | (1) |
|
5.2 Early Cancer Vaccine Attempts |
|
|
98 | (3) |
|
|
|
101 | (1) |
|
5.4 Shifting Attitudes to the Immune System and Cancer |
|
|
102 | (1) |
|
5.5 Interferon: A New Weapon Emerges |
|
|
103 | (1) |
|
5.6 Anti-idiotype Antibodies |
|
|
104 | (1) |
|
5.7 Interleukin and Adoptive Cell Therapy (ACT) |
|
|
105 | (2) |
|
|
|
107 | (2) |
|
|
|
109 | (1) |
|
5.10 Immune Checkpoint Inhibitors |
|
|
110 | (4) |
|
5.11 Stimulatory Checkpoint Molecules |
|
|
114 | (1) |
|
5.12 Conclusion: Immunotherapy Today |
|
|
114 | (12) |
|
|
|
120 | (6) |
|
Chapter 6 Gene Therapy: An Evolving Story |
|
|
126 | (21) |
|
|
|
|
|
126 | (2) |
|
6.2 How Gene Therapy Works |
|
|
128 | (5) |
|
6.2.1 How Genes Cause Disease |
|
|
128 | (2) |
|
6.2.2 How Genes (Might) Fix Disease |
|
|
130 | (1) |
|
6.2.3 Technical Challenges for Gene Therapy |
|
|
131 | (2) |
|
6.3 The Emergence of the Gene Therapy Field |
|
|
133 | (8) |
|
6.3.1 The Scientific Groundwork is Laid |
|
|
134 | (1) |
|
6.3.2 Ethical Questions Are Raised |
|
|
134 | (3) |
|
6.3.3 Preparations Begin for First-in-human Gene Therapy |
|
|
137 | (2) |
|
6.3.4 Gene Therapy Grows Up |
|
|
139 | (2) |
|
6.4 Current Issues in Gene Therapy |
|
|
141 | (2) |
|
|
|
143 | (4) |
|
|
|
144 | (3) |
|
Chapter 7 Stem Cells: An Emerging Field for Medicine |
|
|
147 | (27) |
|
|
|
|
|
|
|
147 | (2) |
|
7.2 The `Stem Cell' Concept |
|
|
149 | (1) |
|
7.3 Haematopoietic Stem Cells (HSCs) |
|
|
149 | (1) |
|
7.4 Bone Marrow Transplantation |
|
|
150 | (2) |
|
7.5 Stem Cell Therapy Beyond BMT |
|
|
152 | (1) |
|
7.6 First Wave of Commercialisation: CD34---Cell Separation and Stem Cell Enrichment |
|
|
153 | (1) |
|
7.7 Second Wave of Commercialisation: Regenerative Medicine |
|
|
154 | (1) |
|
7.8 Mesenchymal Stromal Cells (MSCs) Therapy |
|
|
155 | (2) |
|
7.9 Human Embryonic Stem Cells |
|
|
157 | (2) |
|
|
|
159 | (1) |
|
7.11 Umbilical Cord Banking |
|
|
159 | (2) |
|
7.12 Stem Cell Innovation: The Overall Landscape |
|
|
161 | (1) |
|
7.13 Hurdles to Commercialisation |
|
|
162 | (1) |
|
7.14 Third Wave of Commercialisation: The iPS Cell 2006-2016 |
|
|
163 | (4) |
|
|
|
167 | (7) |
|
|
|
169 | (5) |
|
Chapter 8 Protein Therapeutics and Blinding Diseases |
|
|
174 | (22) |
|
|
|
|
|
|
|
|
|
174 | (1) |
|
8.2 The Eye and Blinding Disease |
|
|
175 | (2) |
|
8.3 Common Blinding Conditions |
|
|
177 | (3) |
|
8.3.1 Cataracts and Glaucoma |
|
|
177 | (1) |
|
8.3.2 Age-related Macular Degeneration (AMD) |
|
|
177 | (2) |
|
8.3.3 Diabetic Macular Edema (DME) |
|
|
179 | (1) |
|
|
|
179 | (1) |
|
8.4 Biological Treatments |
|
|
180 | (1) |
|
8.5 Administering Mab Therapeutics to the Eye |
|
|
180 | (4) |
|
8.5.1 Challenges With Current Routes of Administration |
|
|
180 | (1) |
|
8.5.2 Direct Intravitreal (PVT) Injections to the Vitreous Humour |
|
|
181 | (3) |
|
8.6 The Changing Face of Mab Drugs |
|
|
184 | (2) |
|
|
|
186 | (1) |
|
8.8 Ciliary Neutrophic Factor |
|
|
187 | (1) |
|
8.9 The Challenges Behind the Clinical Development of Ophthalmic Drugs |
|
|
187 | (4) |
|
8.9.1 Anatomical Differences Between Human and Animal Models |
|
|
187 | (1) |
|
8.9.2 Overcoming Anti-drug Antibodies (ADAs) in Animals |
|
|
188 | (1) |
|
8.9.3 Difficulty in Stability Studies |
|
|
188 | (1) |
|
8.9.4 In Vitro Testing Challenges |
|
|
188 | (3) |
|
|
|
191 | (1) |
|
|
|
192 | (4) |
|
|
|
194 | (1) |
|
|
|
194 | (2) |
|
Chapter 9 Synthetic Biology: A Game Changer? |
|
|
196 | (20) |
|
|
|
|
|
196 | (1) |
|
9.2 What's in a Name? The Origins of Synthetic Biology |
|
|
197 | (3) |
|
9.3 Engineering Biology and Biotechnology |
|
|
200 | (2) |
|
9.4 Artemisinin---Synthetic Biology Comes of Age |
|
|
202 | (2) |
|
9.5 Heath Economics---Reality Bites for SynBio Artemisinin |
|
|
204 | (2) |
|
9.6 Synthia---Synthetic Life in the Making |
|
|
206 | (2) |
|
9.7 Synthetic Biology Goes Mainstream---Science for the People by the People |
|
|
208 | (2) |
|
9.8 Ethics, Safety and Playing God |
|
|
210 | (2) |
|
9.9 Dare to Dream, Where Next for Synthetic Biology |
|
|
212 | (2) |
|
|
|
214 | (2) |
|
|
|
214 | (2) |
|
Chapter 10 Synthetic Biology-Engineering Tomorrow's Medicines |
|
|
216 | (25) |
|
|
|
|
|
|
|
216 | (1) |
|
10.2 What Is Synthetic Biology? |
|
|
217 | (2) |
|
10.3 Moving on from Microbes |
|
|
219 | (1) |
|
10.4 Synthetic Biology for Manufacturing Medicines |
|
|
220 | (8) |
|
|
|
221 | (1) |
|
10.4.2 Synthetic Vaccines |
|
|
222 | (1) |
|
10.4.3 Engineering Cells for Drug Discovery |
|
|
223 | (1) |
|
|
|
224 | (2) |
|
10.4.5 Novel Antimicrobials |
|
|
226 | (1) |
|
10.4.6 Mini Organs for Better Toxicity Screening |
|
|
227 | (1) |
|
10.5 Synthetic Cells as Diagnostics and Theranostics |
|
|
228 | (4) |
|
10.5.1 Cellular Prosthesis |
|
|
229 | (2) |
|
10.5.2 Theranostics on the Drawing Board |
|
|
231 | (1) |
|
10.6 Engineering Cell Therapy |
|
|
232 | (4) |
|
10.6.1 Building in Controls |
|
|
232 | (1) |
|
10.6.2 `CAR-T Blanche' for Cancer Therapy |
|
|
233 | (3) |
|
10.7 Medicines and Microbes |
|
|
236 | (2) |
|
|
|
238 | (3) |
|
|
|
238 | (3) |
| Subject Index |
|
241 | |